Belzutifan, HIF-2α Inhibitor, and Clear Cell Renal Cell Carcinoma With Somatic Von-Hippel-Lindau Loss-of-Function Mutation

• Auteurs principaux: Kok Hoe Chan MD (Auteur), Ningjing Li MD (Auteur), Ran Lador MD (Auteur), Mark Amsbaugh MD (Auteur), Anneliese Gonzalez MD (Auteur), Putao Cen MD (Auteur)
• Format: Livre
• Publié: SAGE Publishing, 2024-02-01T00:00:00Z.
• Sujets: article
• Accès en ligne: Connect to this object online.

The Von-Hippel-Lindau (VHL) gene, acting as a tumor suppressor, plays a crucial role in the tumorigenesis of clear cell renal cell carcinoma (ccRCC). Approximately 90% of individuals with advanced ccRCC exhibit somatic mutations in the VHL gene. Belzutifan, orally administered small-molecule inhibit...